Analysts Expect Y-mAbs Therapeutics (YMAB) to Post ($0.44) Earnings Per Share
Shares of Y-mAbs Therapeutics (NASDAQ:YMAB) have earned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1 year consensus target price of $30.50 for the company and are anticipating that the company will post ($0.44) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Y-mAbs Therapeutics an industry rank of 82 out of 255 based on the ratings given to related companies.
A number of analysts have recently commented on the company. Bank of America assumed coverage on Y-mAbs Therapeutics in a research note on Tuesday, October 16th. They issued a “buy” rating and a $26.00 price target for the company. Canaccord Genuity assumed coverage on Y-mAbs Therapeutics in a research note on Tuesday, October 16th. They issued a “buy” rating and a $30.00 price target for the company. Cowen reaffirmed a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Tuesday, October 16th. Finally, BTIG Research assumed coverage on Y-mAbs Therapeutics in a research note on Tuesday, October 16th. They issued a “buy” rating and a $35.00 price target for the company.
Shares of YMAB stock traded up $0.30 on Wednesday, reaching $21.80. The company had a trading volume of 1,521 shares, compared to its average volume of 154,680. Y-mAbs Therapeutics has a 12 month low of $18.00 and a 12 month high of $31.00.
Y-mAbs Therapeutics Company Profile
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Read More: Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.